Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors

https://doi.org/10.1016/0028-3908(83)90239-3Get rights and content

Abstract

Following intraperitoneal administration, the selective cAMP phosphodiesterase (PDE) inhibitors rolipram, ICI 63 197 and Ro 20-1724 were investigated in mice in comparison with imipramine for their effectiveness in two classical test models for prediction of clinical antidepressant activity: antagonism of reserpine-induced hypothermia or hypokinesia and potentiation of yohimbine lethality. Rolipram was approximately 15 times more potent than imipramine or Ro 20-1724 and approximately as potent as ICI 63 197 in antagonizing reserpine-induced hypothermia. The antihypothermic effect of the phosphodiesterase inhibitors occurred at a smaller dose than that of imipramine. In contrast to imipramine, the phosphodiesterase inhibitors reversed reserpine-induced hypokinesia. Rolipram was approximately as potent as ICI 63 197 and about 15 times more potent than Ro 20-1724. Rolipram was approx. 5 times more potent than Ro 20-1724 and approx. as potent as imipramine or ICI 63 197 in potentiating the lethality of yohimbine. In both test models the (−)-isomer of rolipram was approx. 10–15 times more potent than the (+)-isomer, indicating a stereospecific mechanism of action. The present data suggest an antidepressant action of selective cAMP phosphodiesterase inhibitors due to enhancement of central noradrenergic transmission. The hypothesis is put forward that the increase of noradrenaline turnover induced by phosphodiesterase inhibitors with the inhibitory action of the compounds on cAMP metabolism enables more efficient adaptative changes to occur at central synapses resulting in a rapid onset of the antidepressant activity. Preliminary results with rolipram in patients with endogenous depression seem to support this assumption.

References (41)

  • G.W. Arbuthnott et al.

    Is adenylate cyclase the dopamine receptor?

    Med. Biol.

    (1974)
  • J. Axelrod et al.

    Effect of psychotropic drugs on uptake of 3H-norepinephrine by tissue

    Science

    (1961)
  • A. Carlsson et al.

    Effect of reserpine on monoamine synthesis and on apparent dopaminergic receptor sensitivity in rat brain

  • A. Coppen

    The biochemistry of affective disorders

    Br. J. Psychiat.

    (1967)
  • H. Corrodi et al.

    Effects of caffeine on central monoamine neurons

    J. Pharm. Pharmac.

    (1972)
  • H. Dengler et al.

    Effects of drugs on uptake of isotopic norepinephrine by cat tissues

    Nature

    (1961)
  • J.R. Gillette et al.

    Isolation from rat brain of a metabolic product, demethylimipramine, that mediates the antidepressant activity of imipramine

    Experientia

    (1961)
  • A.S. Horn et al.

    Catecholamine uptake by synaptosomes from rat brain. Structure activity relationships of drugs with differential effects on dopamine and norepinephrine neurons

    Molec. Pharmac.

    (1971)
  • W. Kehr

    3-Methoxytyramine and normetanephrine as indicators of dopamine and noradrenaline release in mouse brain in vivo

    J. Neural Trans.

    (1981)
  • W. Kehr et al.

    Regulation of the in vivo synthesis of brain dopamine by presynaptic receptors

  • Cited by (230)

    • Role of tau protein in Alzheimer's disease: The prime pathological player

      2020, International Journal of Biological Macromolecules
      Citation Excerpt :

      APP/PS1 mice treated with Rolipram showed a comparable long-term potentiation (LTP) induction which is prevalently found to be scarce in the APP/PS1 mouse model of AD. Also, Rolipram was noted to enhance the proteasome system by increasing the phosphorylation of PKA (mediator of proteasome function) and other proteasome systems [254–256]. By investigating the connection between neurodegenerative diseases and autophagy has put forward an interesting question of whether modulating autophagy could reduce protein aggregation and ameliorate cell degeneration.

    • Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability

      2019, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      The highest concentrations of PDE4B and PDE4D are found in specific brain regions such as the nucleus accumbens shell and the frontal cortex, which suggests their role in depression, schizophrenia, and cognitive process.13 To date, a plethora of different structurally related molecules have been reported including the first prototypical PDE4-selective inhibitor, rolipram, which has shown behavioral and antidepressant effect in rats and humans.14–16 Another molecule, RO-20-1724, has been shown to exhibit antipsychotic-like properties as well as neuroprotective effect.17,18

    • Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays

      2017, Cellular Signalling
      Citation Excerpt :

      The PDE4 family, composed of four genes (PDE4A-4D), has long been seen as a promising drug target involved in inflammation and psychiatric disease. For example, rolipram, the drug that defines the PDE4 family, displays both anti-inflammatory and anti-depressant activity [7,8]. However, efforts to develop rolipram, and most other PDE4 inhibitors, as a therapeutic have been hampered by common side-effects such as emesis and nausea [9], although some success has been seen with Roflumilast to treat chronic obstructive pulmonary disease and Apremilast to treat psoriasis and psoriatic arthritis [10].

    View all citing articles on Scopus
    View full text